curasan AG, DE0005494538

curasan AG, DE0005494538

03.04.2017 - 12:13:10

Christine Uekert: new CFO at curasan

Finance specialist with turnaround experience Successor to Dr. Erwin Amashaufer as planned Focus on modernization of the financial architecture

Kleinostheim, 3 April 2017 - curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, has appointed Christine Uekert as chief financial officer with effect from 3 April.

Uekert succeeds Dr. Erwin Amashaufer, who is retiring, in the position as a Management Director. At the same time, Uekert will become the CFO of the American subsidiary curasan Inc. in Research Triangle Park, North Carolina, in order to ensure the rapid implementation of its planned integration in the commercial structures of curasan AG and the efficient coordination of all financial processes.

Uekert has extensive experience in the areas of finance and controlling in internationally operative, innovative and especially growing companies. Most recently, Ms. Uekert, who holds a degree in business economics, was the chief financial officer at Centogene AG, a global diagnostics company. There, she was responsible for developing the financial architecture and expansion strategy, and successfully supported growth corresponding to more than a tenfold increase in sales within five years. Prior to that, she held several management positions at biotechnology and technology companies such as ProBioGen AG, OD-OS GmbH, SPM Technologies GmbH and SAP Systems Integration AG.

Michael Schlenk, CEO of curasan AG, is very pleased to have Christine Uekert on board. "During our many years of collaboration at Centogene, I came to know and value the excellent management senses as well as the industrial and financial expertise of Christine Uekert. I am delighted to welcome this proven financial expert and manager to our company; she has a profound knowledge of dynamic, international and fast-growing structures and will continue and further develop the successful strategy of curasan."

To ensure a smooth transition, Dr. Erwin Amashaufer, who has headed finance and administration of the company since 2004 and who is now retiring, will assist her in the first few weeks. "Dr. Amashaufer was the one who made the initial phase of my work as CEO in autumn of 2014 significantly easier. He has always provided excellent and reliable support with his knowledge and experience," recalled Schlenk. "We've weathered a number of storms together and put the company on a new course. On my own behalf and on behalf of all our staff members, I'd like to express our warm thanks and wish him all the very best in the future."

Christine Uekert said, "Together with the experienced management team at curasan, I look forward to the opportunity and the challenge of shaping the strategic shift initiated in 2014 and the corresponding transformation of the corporate group for the next major phases of growth on a sustained basis."

 

About curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan.

curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

Contact: Ingo Middelmenne Head of Investor Relations Tel. +49 6027 40900-45 Fax +49 6027 40900-39 ingo.middelmenne@curasan.de Andrea Weidner Head of Corporate Communications Tel. +49 6027 40900-51 Fax +49 6027 40900-39 andrea.weidner@curasan.de www.curasan.de  

03.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: curasan AG Lindigstraße 4 63801 Kleinostheim

Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

561141  03.04.2017 

@ dgap.de